HETEROCYCLES, Vol. 68, No. 10, 2006
2033
ACKNOWLEDGEMENTS
The authors would like to thank the National Science Council (NSC-95-2113-M-390-003-MY2) of the
Republic of China for financial support.
REFERENCES
1. For a review, see: P. Remuzon, Tetrahedron, 1996, 52, 13803.
2. For related references, see: (a) J. Azizian, A. R. Karimi, Z. Kazemizadeh, A. A. Mohammadi, and M.
R. Mohammadizadeh, J. Org. Chem., 2005, 70, 1471. (b) J. R. Del Valle and M. Goodman, Angew.
Chem., Int. Ed., 2002, 41, 1600. (c) T. Gonzalez, O. Abad, M. C. Santano, and C. Minguillon,
Synthesis, 2004, 1171. (d) T. Honda, R. Takahashi, and H. Namiki, J. Org. Chem., 2005, 70, 499. (e)
X.-L. Qiu and F.-L. Qing, Bioorg. Med. Chem., 2005, 13, 277. (f) G. Pandey and G. Lakshmaiah,
Synlett, 1994, 277. (g) G. Han, M. G. LaPorte, J. J. Folmer, K. M. Werner, and S. M. Weinreb, J.
Org. Chem., 2000, 65, 6293. (h) P. G. Houghton, G. R. Humphrey, D. J. Kennedy, D. C. Roberts,
and S. H. B. Wright, J. Chem. Soc., Perkin Trans. 1, 1993, 1421. (i) O. Tamura, T. Yanagimachi,
and H. Ishibashi, Tetrahedron: Asymmetry, 2003, 14, 3033. (j) H. Hu and H. Zhai, Synlett, 2003,
2129. (k) H. J. Breslin, M. J. Kukla, D. W. Ludovici, R. Mohrbaeher, W. Ho, M. Miranda, J. D.
Rodgers, T. K. Hitchens, G. Leo, D. A. Gauthier, Y. H. Chih, M. K. Scott, E. De Clercq, R. Pauwels,
K. Andries, M. A. C. Janssen, and P. A. Janssen, J. J. Med. Chem., 1995, 38, 771. (l) M. Y. Chang, S.
T. Chen, and N. C. Chang, Heterocycles, 2003, 60, 1203. (m) M. Y. Chang and H. P. Chen,
Heterocycles, 2005, 65, 1705. (n) M. Y. Chang, H. P. Chen, C. Y. Lin, and C. L. Pai, Heterocycles,
2005, 60, 1999. (o) M. Y. Chang, C. L. Pai, and H. P. Chen, Tetrahedron Lett., 2005, 46, 7705. (p)
M. Y. Chang, Y. H. Kung, and S. T. Chen, Tetrahedron Lett., 2006, 47, 4865.
3. (a) B. Lippert, B. W. Metcalf, M. J. Jung, and P. Casara, Eur. J. Biochem., 1977, 74, 441. (b) S. M.
Grant and R. C. Heel, Drugs, 1991, 41, 889. (c) B. W. Metcalf, Biochem. Pharmacol., 1979, 28,
1705. (d) S. Sarhan, P. Casara, B. Knodgen, and N. Seiler, Neurochem. Res., 1991, 16, 285.
4. For racemic syntheses of vigabatrin® (2), see: (a) B. Metcalf and P. Casara, Tetrahedron Lett., 1975,
3337. (b) B. Metcalf and P. Casara, J. Chem. Soc., Chem. Commun., 1979, 119. (c) G. Deleris, J.
Dunogues, and A. Gadras, Tetrahedron, 1988, 44, 4243. (d) P. Casara, Tetrahedron Lett., 1994, 35,
3049.
5. For catalytic enantioselective syntheses, see: (a) C. E. Anderson and L. E. Overman, J. Am. Chem.
Soc., 2003, 125, 12412. (b) L. E. Overman and T. P. Remarchuk, J. Am. Chem. Soc., 2002, 124, 12.
(c) B. M. Trost and R. C. Lemoine, Tetrahedron Lett., 1996, 37, 9161. (d) B. M. Trost, R. C. Bunt, R.
C. Lemoine, and T. L. Calkins, J. Am. Chem. Soc., 2000, 122, 5968. For stereospecific syntheses
starting from α-amino acids, see: (e) Z.-Y. Wei and E. E. Knaus, Tetrahedron, 1994, 50, 5569. (f)